ADA instant detection test strip and kit for adalimumab drug

A technology for detecting adalimumab and test strips, which is applied in the direction of resisting vector-borne diseases, measuring devices, instruments, etc., can solve problems such as unsuitable popularization, time-consuming and labor-consuming, and long time required to obtain results, and achieve results The effect of rapid interpretation, no need for equipment, and reduced operation difficulty

Pending Publication Date: 2022-07-12
邹灵龙
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The traditional ADA detection method is the ELISA method, which not only takes a long time to obtain the results, but also needs to be matched with expensive instrument

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • ADA instant detection test strip and kit for adalimumab drug
  • ADA instant detection test strip and kit for adalimumab drug
  • ADA instant detection test strip and kit for adalimumab drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Preparation of ADA point-of-care test strips and kits for adalimumab:

[0047] 1. Gold spraying treatment: The adalimumab drug-45nm colloidal gold conjugate and chicken IgY monoclonal antibody colloidal gold conjugate were sprayed evenly on the sample gold label at a concentration of 4 μL / cm and 1 mg / mL respectively. On the one-piece pad, diluent I (0.1M Tris, 1% BSA, 2% sucrose, pH 8.0) was placed at 37°C for overnight treatment.

[0048] The preparation methods of adalimumab colloidal gold conjugate and chicken IgY monoclonal antibody colloidal gold conjugate are as follows:

[0049] Add 20ml of the prepared colloidal gold particles to the beaker, add 100μl of 0.1M potassium carbonate, rotate at 200 rpm on a magnetic stirrer, and react for 5min;

[0050] Add 100 μl of 1 mg / ml antibody to be labeled into the beaker, and react at 200 rpm on a magnetic stirrer for 30 min;

[0051] Add 200 μl of 10% BSA to the beaker, and react for 15 min on a magnetic stirrer at 200 rp...

Embodiment 2

[0058] Use the adalimumab antidrug antibody detection kit of Example 1 to confirm the critical point. The method of use is as follows: place the test strip horizontally, add 10ul of the sample to the sample addition hole, and then dropwise add 2 to 3 drops of the sample diluent , and observe the results after standing for 15 minutes.

[0059] The results are determined as follows:

[0060] Positive: A red line appears on each of the quality control line (hereinafter referred to as C line) and the detection line (hereinafter referred to as T line), indicating the presence of adalimumab ADA in the sample, and the test result is positive.

[0061] Negative: Only the quality control line (C line) has a red line, and the detection line (T line) has no red line, indicating that there is no adalimumab ADA in the sample or the ADA is below the detection level, and the test result is negative.

[0062] Invalid: There is no red line on the control line (C line), which means it is inval...

Embodiment 3

[0072] Positive sample confirmation:

[0073] Since this method is mainly based on operator observation and judgment, in order to further explore the disputed range between T / C value and the operator's direct observation and judgment results, and to ensure that the direct interpretation results are all positive samples, the experiments were conducted by preparing positive samples with different concentrations. The experimental operation was performed according to the operation flow of Example 3. The experimental results are shown in Table 2.

[0074] Table 2-1 Test results of positive samples

[0075]

[0076] Table 2-2 Test results of positive samples

[0077]

[0078] From the above test results, it was found that when the ADA concentration was 50ng / mL, there was no objection to the interpretation results, and they were all judged as positive results (Table 2-1 and Table 2-2). In order to further confirm the critical area of ​​the operator's direct interpretation of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an ADA instant detection test strip and kit for adalimumab drug, and belongs to the technical field of clinical rapid (instant) detection and anti-drug antibody bioanalysis, the ADA instant detection test strip comprises a sample gold-labeled integrated pad, a nitrocellulose membrane and absorbent cotton; a sample adding hole and a gold marking line are arranged on the sample-gold marking integrated pad; an adalimumab colloidal gold conjugate and a chicken IgY colloidal gold conjugate are sprayed on the gold marking line; a detection line and a quality control line are arranged on the nitrocellulose membrane, a mouse anti-human IgG monoclonal antibody is sprayed on the detection line, and a goat anti-chicken IgY polyclonal antibody is sprayed on the quality control line. By adopting the ADA instant detection test strip provided by the invention, a detection result can be obtained within 15 minutes, and expensive instruments are not needed.

Description

technical field [0001] The invention belongs to the technical field of clinical rapid (instant) detection and anti-drug antibody biological analysis, and in particular relates to an ADA instant detection test strip and a kit for adalimumab. Background technique [0002] Immunogenicity generally refers to the ability of a therapeutic protein drug to induce an autoimmune or immune-related response. When therapeutic protein products are used as disease treatment drugs to produce unexpected immune responses, it will bring certain risks to the safety and efficacy of the drugs, mainly causing the human body to produce anti-drug antibodies (ADA), affecting the biological activity and pharmacokinetics of the drugs. Therefore, the efficacy of the drug is reduced or disappeared, and more seriously, it may cause safety hazards to the human body. [0003] In the process of pre-marketing clinical trials of drugs, immunogenicity is an important drug safety indicator, which provides an im...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/541G01N33/559
CPCG01N33/541G01N33/559Y02A50/30
Inventor 邹灵龙梁宇
Owner 邹灵龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap